HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Hari, P. [1 ]
Lin, H. M. [2 ]
Zhu, Y. [2 ]
Berg, D. [2 ]
Richardson, P. [3 ]
Moreau, P. [4 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P735
引用
收藏
页码：297 / 298
页数：2
相关论文
共 50 条
  • [41] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
    Biran, Noa
    Siegel, David Samuel DiCapua
    Berdeja, Jesus G.
    Raje, Noopur S.
    Cornell, Robert F.
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy
    Landgren, Carl Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study
    Chen, Wenming
    Xia, Zhongjun
    Fang, Baijun
    Fu, Chengcheng
    Li, Wei
    Yang, Linhua
    Ke, Xiaoyan
    Jiang, Hua
    Weng, Jianyu
    Liu, Li
    Zhao, Yaozhong
    Zhang, Xuejun
    Liu, Aichun
    Huang, Zhongxia
    Shi, Qingzhi
    Gao, Yuhuan
    Chen, Xiequn
    Pan, Ling
    Cai, Zhen
    Wang, Zhao
    Wang, Yafei
    Zhang, Yizhuo
    Fan, Yaqun
    Hou, Ming
    Yang, Shifang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S143 - S143
  • [43] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Tohru Izumi
    Takuya Komeno
    Yasuhito Terui
    Takaaki Chou
    Takashi Ikeda
    Deborah Berg
    Shinichi Fukunaga
    Kenkichi Sugiura
    Makoto Sasaki
    International Journal of Clinical Oncology, 2022, 27 : 224 - 233
  • [44] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Izumi, Tohru
    Komeno, Takuya
    Terui, Yasuhito
    Chou, Takaaki
    Ikeda, Takashi
    Berg, Deborah
    Fukunaga, Shinichi
    Sugiura, Kenkichi
    Sasaki, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 224 - 233
  • [45] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Tuchman, Sascha A.
    Rosenblatt, Jacalyn M.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Masone, Kelly
    Warren, Diane
    Redd, Robert A.
    Grayson, Dena
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [46] A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
    Leonard, John
    Batlevi, Connie Lee
    Gabrail, Nashat
    Pagel, John M.
    Yang, Jay
    Whalen, Jennifer
    Adib, Deyaa
    Morschhauser, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S279 - S279
  • [47] OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide
    Sonneveld, Pieter
    Schjesvold, Fredrik
    Robak, Pawel
    Rossjey, Viktor
    Pour, Ludk
    Minarik, Jiri
    Delimpasi, Sosana
    Legic, Wojciech
    Salogub, Galina
    Harmenberg, Johan
    Byrne, Catriona
    Nordstrom, Eva
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S25 - S25
  • [48] A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Rocafiguera, Albert Oriol
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Sherbenou, Daniel Wayne
    Avivi, Irit
    Iida, Shinsuke
    Matsumoto, Morio
    Usmani, Saad Zafar
    Jagannath, Sundar
    Rodriguez-Otero, Paula
    Kher, Uma
    Farooqui, Mohammed Z. H.
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    Kumar, Shaji K.
    Harrison, Simon J.
    Cavo, Michele
    de la Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth A.
    Hong, Wan-Jen
    Freise, Kevin J.
    Yang, Xiaoqing
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Ward, James E.
    Maciag, Paulo C.
    Moreau, Philippe
    LANCET ONCOLOGY, 2020, 21 (12): : 1630 - 1642
  • [50] Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
    Bahlis, Nizar
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Qi, Ming
    San-Miguel, Jesus F.
    BLOOD, 2018, 132
12345